US 12,298,302 B2 · Systems and methods for rheumatoid arthritis biomarker detection

Abstract

Embodiments provide for devices and methods of use for detecting one or more biomarkers of rheumatic disease in a subject. In an example, a method includes detecting citrullinated human serum albumin (HSA) in a biological sample via obtaining the biological sample from a subject, applying the biological sample to a lateral flow device under conditions sufficient for formation of an immunocomplex comprising anti-HSA antibody coupled to citrullinated HSA that is in turn coupled to anti-citrullinated HSA autoantibody, determining a quantity of the immunocomplex, and managing rheumatic disease associated with the subject. In this way, rheumatic disease may be effectively managed based at least in part on amounts of citrullinated HSA detected via rapid point-of-care test methodology.

Claims9

Dependent claims

A method of detecting and quantifying anti-citrullinated human serum albumin (HSA) autoantibody in a biological sample, comprising:

obtaining the biological sample from a subject;
applying the biological sample to a lateral flow device, wherein the lateral flow device comprises anti-human IgA, IgG, and IgM antibodies affixed to a surface, under conditions sufficient for formation of an immunocomplex, wherein the immunocomplex comprises anti-citrullinated HSA autoantibody bound to citrullinated HSA;
applying to the lateral flow device an anti-HSA antibody coupled to a detectable label, wherein the anti-HSA antibody is capable of binding the citrullinated HSA in the immunocomplex;
and
detecting a quantity of the immunocomplex to determine a quantity of anti-citrullinated HSA autoantibody.

2 more elements

Dependencies are inferred from the claim text.

Systems and methods for rheumatoid arthritis biomarker detection

Life of this patent

Systems and methods for rheumatoid arthritis biomarker detection

Life of this patent

Abstract

Claims9